Draxis Health Starts Phase III Fibrimage
Trials
MISSISSAUGA, Ont. -- Draxis Health Inc. (DRAX)
said its Draximage Inc. radiopharmaceutical subsidiary
has started Phase III
clinical trials in Canada
for Fibrimage, a diagnostic tool for deep vein
thrombosis, or DVT.
In a news release, the drug company
said the trial should involve 130 patients and be
completed by the end of the year.
DVTs are blood clots
that form in the lower limbs and can lead to a
pulmonary embolism, or a blockage of blood flow to the
lungs, a
condition that kills about 200,000 people a
year in the U.S., it said.
It said Fibrimage is
based on Fibrin Binding Domain, a recombinant
polypeptide developed by Bio-Technology General Corp.
(BTGC) and licensed to Draximage on an exclusive,
worldwide basis